Where some of the biggest drugmakers stand after Q2

Mackenzie Bean - Print  | 

With the end of the second quarter wrapping up, drug industry giants are reporting a variety of financial results.

Here's where six major drugmakers stand after the end of the second quarter:

Bristol-Myers Squibb reported second quarter revenues of $4.9 billion, a 17 percent increase from the second quarter of 2015. Sales of the cancer drug Opdivo, which reached $840 million this quarter, are expected to keep growing despite competition from Merck's Keytruda. Sales of Yervoy, a melanoma treatment often paired with Opdivo or Keytruda, decreased 19 percent to $241 million for the quarter. Bristol-Myers Squibb now expects total earnings of $2.55 to $2.65 per share for the year.

Astrazeneca saw second quarter earnings decrease by almost a third due to generic competition of the company's best-selling cholesterol drug Crestor. Core earnings fell 31 percent year over year to 83 cents per share, while revenue dropped 11 percent to $5.60 billion per share compared to the second quarter of 2015. However, the Britain-based company's lung cancer drug Tagrisso surpassed expectations with second quarter sales of $92 million. Astrazeneca expects a low to mid single-digit percent decrease in revenue and core earnings at constant exchange rates throughout the remainder of 2016.

Eli Lily reported better-than-expected sales for the second quarter, thanks to the success of the Indianapolis-based company’s new drugs. Trulicity — an injectable diabetes treatment — hit sales of $201 million. Sales of the two-year-old drug Cyramza, used to treat stomach and lung cancer, jumped 68 percent from the second quarter of 2015 to $147 million. Eli Lily's revenue hit $5.4 billion in the second quarter, marking a 9 percent increase from last year and exceeding Wall Street's prediction of $5.15 billion.

Celgene posted net sales of $2.74 billion in the second quarter, marking a 22 percent increase year over year. The Summit, N.J.-based company had a net income of $598 million for the quarter, compared to $356 million for the second quarter of 2015. Sales of Revlimid, a treatment for multiple myeloma, jumped 18 percent to $1.70 billion. Celgene now expects adjusted earnings of $5.70 to $5.75 per share for 2016, compared to the original estimate of $5.60 to $5.70 per share.

Merck reported an unexpected revenue increase in the second quarter due to the success of its cancer drug Keytruda and new hepatitis treatments. The Kenilworth, N.J.-based drugmaker posted sales of $314 million for Keytruda and $112 million for its new hepatitis C drug Zepatier in the second quarter. Merck recorded a second quarter profit of $1.21 billion, or 43 cents a share, compared to $687 million, or 24 cents a share, in the same quarter the year prior. Sales grew 0.6 percent to $9.84 billion this quarter, compared to $9.78 billion in the second quarter of 2015.

More articles on the drug market:

J&J sells experimental asthma drug to GSK for $230M
Sen. Bernie Sanders' DNC speech tackles high prescription drug costs: 4 things to know
4 latest FDA approvals


© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.